Published in Antimicrob Agents Chemother on March 01, 2004
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva. Infect Immun (2005) 1.37
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother (2005) 1.30
Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother (2007) 0.95
Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag (2008) 0.92
Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob Agents Chemother (2005) 0.82
Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections. Infect Dis Ther (2015) 0.79
Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms. P T (2008) 0.75
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother (2010) 0.75
Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother (1980) 23.54
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep (1997) 5.30
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet (1998) 4.08
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother (1999) 1.83
In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother (2001) 1.66
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother (1999) 1.41
Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis. Antimicrob Agents Chemother (2003) 1.04
Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths. PLoS Genet (2009) 8.51
Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int (2008) 2.06
Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol (2013) 2.06
Diversity of individual dynamic patterns of emergence of resistance to quinolones in Escherichia coli from the fecal flora of healthy volunteers exposed to ciprofloxacin. J Infect Dis (2012) 1.58
Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.49
Pathogenicity-associated islands in extraintestinal pathogenic Escherichia coli are fitness elements involved in intestinal colonization. J Bacteriol (2010) 1.32
Accuracy and potential usefulness of triplex real-time PCR for improving antibiotic treatment of patients with blood cultures showing clustered gram-positive cocci on direct smears. J Clin Microbiol (2008) 1.29
Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother (2003) 1.26
Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis (2009) 1.23
Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era. Crit Care (2010) 1.20
Mutator phenotype confers advantage in Escherichia coli chronic urinary tract infection pathogenesis. FEMS Immunol Med Microbiol (2005) 1.19
The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One (2012) 1.19
Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir Immune Defic Syndr (2011) 1.17
Evaluation of the management of postoperative aseptic meningitis. Clin Infect Dis (2007) 1.15
Role of N-acetylglucosaminidase and N-acetylmuramidase activities in Enterococcus faecalis peptidoglycan metabolism. J Biol Chem (2008) 1.13
Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother (2005) 1.12
Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia. J Clin Microbiol (2010) 1.11
Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother (2009) 1.11
Comparative study of postoperative and spontaneous pyogenic spondylodiscitis. Semin Arthritis Rheum (2005) 1.11
Etiologies and outcome of acute respiratory failure in HIV-infected patients. Intensive Care Med (2009) 1.09
Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis. Antimicrob Agents Chemother (2003) 1.04
Spinal tuberculosis: a longitudinal study with clinical, laboratory, and imaging outcomes. Semin Arthritis Rheum (2006) 1.03
Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis (2005) 1.03
Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone. J Antimicrob Chemother (2010) 1.00
Relationship between the level of acquired resistance to gentamicin and synergism with amoxicillin in Enterococcus faecalis. Antimicrob Agents Chemother (2005) 0.97
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol (2014) 0.96
Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antivir Ther (2005) 0.95
Characteristics of human intestinal Escherichia coli with changing environments. Environ Microbiol (2008) 0.93
Effects of chemical and physical agents on viability and infectivity of Encephalitozoon intestinalis determined by cell culture and flow cytometry. Antimicrob Agents Chemother (2002) 0.92
Technetium 99m-labeled annexin V scintigraphy of platelet activation in vegetations of experimental endocarditis. Circulation (2008) 0.91
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS (2008) 0.91
Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission. Antimicrob Agents Chemother (2010) 0.90
Three-month antibiotic therapy for early-onset postoperative spinal implant infections. Clin Infect Dis (2012) 0.90
Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis. Antimicrob Agents Chemother (2006) 0.90
Effects of single and multiple pathogenicity island deletions on uropathogenic Escherichia coli strain 536 intrinsic extra-intestinal virulence. Int J Med Microbiol (2010) 0.89
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis (2012) 0.89
Do case vignettes accurately reflect antibiotic prescription? Infect Control Hosp Epidemiol (2011) 0.89
Impact of peptidoglycan O-acetylation on autolytic activities of the Enterococcus faecalis N-acetylglucosaminidase AtlA and N-acetylmuramidase AtlB. FEBS Lett (2009) 0.87
Clinical outcome after a totally implantable venous access port-related infection in cancer patients: a prospective study and review of the literature. Medicine (Baltimore) (2012) 0.87
Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl (2005) 0.86
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase. Antimicrob Agents Chemother (2012) 0.85
Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther (2010) 0.85
Contribution of the autolysin AtlA to the bactericidal activity of amoxicillin against Enterococcus faecalis JH2-2. Antimicrob Agents Chemother (2009) 0.85
Tuberculous cerebral vasculitis: retrospective study of 10 cases. Eur J Intern Med (2011) 0.85
Ureaplasma urealyticum destructive septic arthritis in a patient with systemic lupus erythematosus after rituximab therapy. Joint Bone Spine (2010) 0.84
Evaluation of 99mTc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections. Eur J Nucl Med Mol Imaging (2007) 0.84
Acute pulmonary embolism: a rare complication of a large non-parasitic hepatic cyst. Eur J Gastroenterol Hepatol (2004) 0.84
Plasmidic qnrA3 enhances Escherichia coli fitness in absence of antibiotic exposure. PLoS One (2011) 0.84
Role of hypermutability on bacterial fitness and emergence of resistance in experimental osteomyelitis due to Staphylococcus aureus. FEMS Immunol Med Microbiol (2007) 0.83
The in vitro contribution of autolysins to bacterial killing elicited by amoxicillin increases with inoculum size in Enterococcus faecalis. Antimicrob Agents Chemother (2010) 0.81
aes, the gene encoding the esterase B in Escherichia coli, is a powerful phylogenetic marker of the species. BMC Microbiol (2009) 0.81
The interaction between a non-pathogenic and a pathogenic strain synergistically enhances extra-intestinal virulence in Escherichia coli. Microbiology (2010) 0.81
Severe Actinobacillus ureae meningitis in an immunocompromised patient: report of one case and review of the literature. Scand J Infect Dis (2007) 0.81
Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains. Antimicrob Agents Chemother (2010) 0.80
Recurrent valvular replacement due to exacerbation of Behcet's disease by Streptococcus agalactiae infection. Eur J Intern Med (2003) 0.80
Antibiotic use: knowledge and perceptions in two university hospitals. J Antimicrob Chemother (2011) 0.80
Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis. J Infect Dis (2003) 0.80
Broad-range 16S rRNA PCR with cerebrospinal fluid may be unreliable for management of postoperative aseptic meningitis. J Clin Microbiol (2010) 0.79
Predominant role of host proteases in myocardial damage associated with infectious endocarditis induced by Enterococcus faecalis in a rat model. Infect Immun (2013) 0.79
Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model. Orphanet J Rare Dis (2014) 0.79
Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment. Blood Cells Mol Dis (2012) 0.79
Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease. Blood Cells Mol Dis (2010) 0.78
Raltegravir-based regimens are effective in HIV-1 group O-infected patients. J Acquir Immune Defic Syndr (2012) 0.78
Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics. Antimicrob Agents Chemother (2006) 0.78
Trend of plasmid-mediated quinolone resistance genes at the Children's Hospital in Tunisia. J Med Microbiol (2013) 0.77
Bone involvement in generalized crystal-storing histiocytosis. J Rheumatol (2006) 0.77
Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART. AIDS (2008) 0.77
[Infections associated with orthopaedic devices]. Rev Prat (2014) 0.77
Optimization of bacterial diagnosis yield after needle aspiration in immunocompetent adults with brain abscesses. Neurosurgery (2008) 0.77
Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet (2013) 0.77
Hypoparathyroidism preceding Riedel's thyroiditis. Eur J Intern Med (2003) 0.75
Characteristics of and risk factors for severe neurological deficit in patients with pyogenic vertebral osteomyelitis: A case-control study. Medicine (Baltimore) (2017) 0.75
Influence of VanD type resistance on activities of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecium. Antimicrob Agents Chemother (2003) 0.75
Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). HIV Clin Trials (2010) 0.75
Risk factors for Clostridium difficile infection in a hepatology ward. Infect Control Hosp Epidemiol (2007) 0.75
Author's reply to: Vandijck et al. Enterobacteriaceae bacteremia after liver transplantation. Transpl Int (2009) 0.75
Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics. Antimicrob Agents Chemother (2002) 0.75
Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (2009) 0.75
Pandemic Influenza A (H1N1) Infection among HIV-Infected Adults in France. J Int Assoc Physicians AIDS Care (Chic) (2011) 0.75